Article Text
Statistics from Altmetric.com
We read the paper written by Kaneko et al with great interest.1 This study demonstrates the safety and efficacy of tocilizumab in patients with adult-onset Still’s disease (AOSD). This randomised placebo-controlled study could be one of the pioneer studies about the use of biological therapy in AOSD. We wanted to ask about some raising concerns.
ACR20, ACR50 and ACR70 responses were used as composite indexes to assess disease activity. In the studies which investigate the effectiveness of a biologic agent in rheumatoid arthritis, general approach is to allow non-steroidal anti-inflammatory drugs (NSAID) if the dose had been stable for a while.2 However, we could not find any data of NSAIDs …
Footnotes
Handling editor Josef S Smolen
Contributors All authors contributed equally.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- Correspondence response